Skip to main content

Advertisement

Table 4 In vivo anti-cancer activity of identified GpM components

From: Anti-cancer effects of Gynostemma pentaphyllum (Thunb.) Makino (Jiaogulan)

Component Animal model Anti-cancer activitya Reference
Gypenosides Nude mice: xenografted with human oral cancer SAS cells 65.76 % (tumor size, 20 mg/kg for 28 days) [89]
Gypenosides BALB/c mice: injected with human leukemia WEHI-3 cells 150 % (survival rate, 2 mg/kg for 2 weeks) 175 % (survival rate, 4 mg/kg for 2 weeks) [90]
Gypenosides Nude mice: xenografted with human leukemia HL-60 cells 44 % (tumor size, 20 mg/kg for 28 days) [91]
Gypenosides BALB/c mice: xenografted with murine S180 sarcoma cells 39.57 % (tumor size, 30 mg/kg for 4 days) [92]
Gypenosides BALB/c mice: xenografted with murine colorectal cancer CT-26 cells 75 % (tumor size, 25 mg/kg for 19 days) 55 % (tumor size, 50 mg/kg for 19 days) 26 % (tumor size, 50 mg/kg + 5 mg/kg 5-Fu for 19 days) [93]
Gypenosides Apc Min/+ mice: intestinal neoplasia model 66.06 % (polyps number, 500 mg/kg for 4 weeks) 59.92 % (polyps number, 750 mg/kg for 4 weeks) [94]
Gypenosides Apc Min/+ mice: intestinal neoplasia model 59.32 % (polyps number, 500 mg/kg for 8 weeks) [95]
Polysaccharide BALB/c mice: xenografted with murine S180 sarcoma cells 62.77 % (tumor size, 100 mg/kg for 14 days) 59.24 % (tumor size, 200 mg/kg for 14 days) [97]
Polysaccharide ICR mice: xenografted with mouse hepatoma H22 cells 62.89 % (tumor size, 50 mg/kg for 10 days) 49.22 % (tumor size, 200 mg/kg for 10 days) [20]
  1. aThe anti-cancer activities of components of GpM are expressed as the percentage of control (readout, dose)